Gastric cancer with peritoneal metastasis or positive peritoneal cytology.
Conditions
Interventions
S-1 was administered orally at a dose 80mg/m2/day for 14 consecutive days, followed by 7days of rest. PTX was administered intravenou at a dose of 50mg/m2 and intraperitoneal at a dose of 20mg/m2 on d
Sponsors
Tottori University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) histologically proven primar gastric adenocarcinoma. 2) Peritneal metastasis and/or cancer cells on peritoneal cytology. 3) Adequate function of important organs (witin 14 days before registration). Neutrocyte >= 1,000/mm3 Hemoglobin >= 8.0g/dl Platelet >= 75,000/mm3 serum transaminases < 100U/L Total Bilirubin <= 3.0mg/dL Creatinine clearance >= 30ml/min 4) Eastern Cooperative Oncology Group performance status 0-2 5) Age >= 20, < 85 years 6) Written informed consent.
Exclusion criteria
Exclusion criteria: 1)The absence of metastasis to distant organ sites except the retroperitoneum, ovary and abdominal lymph nodes. 2)Contraindication to S-1 or paclitaxel. 3)Apparent infection or inflammation. 4)Sever heart disease. 5)Sever complication. 6)Gastrointestinal bleeding requiring blood transfusion repeatedly. 7)Pregnancy, breast feeding or intention to become pregnant. 8)Judeged inappropriate for this trial for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate. three year overall survival. Progression free survival. | — |
Countries
Japan
Contacts
Public ContactHirohiko Kuroda
Tottori University School of Medicine Division of Surgical Oncology
Outcome results
None listed